SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
Dexcom launched its first over-the-counter continuous glucose monitor called Stelo on Monday. Users can buy a one-month supply online for $99, or sign up for an ongoing subscription at $89 a month.
Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...
SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users ...
Four years ago, my life changed after a heart attack at the age of 33. While a quick coronary angioplasty meant my heart was mostly fine, the tests conducted at the same time revealed a bigger chronic ...
Monitoring your health stats, from steps to heart rate, can help you get a handle on your fitness goals. But lately, we've seen technology that takes things a step further, enabling at-home tracking ...
The Stelo CGM is meant to give Type 2 diabetics who don’t need insulin a more affordable way to monitor their blood sugar. The Stelo CGM is meant to give Type 2 diabetics who don’t need insulin a more ...
Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results